Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients.
Nádasdi Á, Sinkovits G, Bobek I, Lakatos B, Förhécz Z, Prohászka ZZ, Réti M, Arató M, Cseh G, Masszi T, Merkely B, Ferdinandy P, Vályi-Nagy I, Prohászka Z, Firneisz G. Nádasdi Á, et al. Among authors: bobek i. Biomark Med. 2022 Apr;16(5):317-330. doi: 10.2217/bmm-2021-0717. Epub 2022 Feb 23. Biomark Med. 2022. PMID: 35195023 Free PMC article.
Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.
Sinkovits G, Mező B, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Sinkovits G, et al. Among authors: bobek i. Front Immunol. 2021 Mar 25;12:663187. doi: 10.3389/fimmu.2021.663187. eCollection 2021. Front Immunol. 2021. PMID: 33841446 Free PMC article. Clinical Trial.
Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
Sinkovits G, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Mező B, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Sinkovits G, et al. Among authors: bobek i. Thromb Haemost. 2022 Feb;122(2):240-256. doi: 10.1055/s-0041-1740182. Epub 2022 Jan 21. Thromb Haemost. 2022. PMID: 35062036 Free PMC article.
Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study.
Henry BM, Sinkovits G, Szergyuk I, de Oliveira MHS, Lippi G, Benoit JL, Favaloro EJ, Pode-Shakked N, Benoit SW, Cooper DS, Müller V, Iványi Z, Gál J, Réti M, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Hurler L, Kajdácsi E, Cervenak L, Mező B, Kiszel P, Masszi T, Vályi-Nagy I, Prohászka Z. Henry BM, et al. Among authors: bobek i. Front Med (Lausanne). 2022 Apr 29;9:796109. doi: 10.3389/fmed.2022.796109. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35572977 Free PMC article.
Common points of therapeutic intervention in COVID-19 and in allogeneic hematopoietic stem cell transplantation associated severe cytokine release syndrome.
Gopcsa L, Bobek I, Bekő G, Lakatos B, Molnár E, Réti M, Reményi P, Sinkó J, Szlávik J, Tatai G, Vályi-Nagy I. Gopcsa L, et al. Among authors: bobek i. Acta Microbiol Immunol Hung. 2021 Nov 19. doi: 10.1556/030.2021.01620. Online ahead of print. Acta Microbiol Immunol Hung. 2021. PMID: 34797216
Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab.
Lakatos B, Szabo BG, Bobek I, Gopcsa L, Beko G, Kiss-Dala N, Petrik B, Gaspar Z, Farkas BF, Sinko J, Remenyi P, Szlavik J, Valyi-Nagy I. Lakatos B, et al. Among authors: bobek i. Acta Microbiol Immunol Hung. 2021 Aug 6. doi: 10.1556/030.2021.01526. Online ahead of print. Acta Microbiol Immunol Hung. 2021. PMID: 34370690
50 results